Gemcitabine HCl Market

Gemcitabine HCl Market Outlook (2023 to 2033)

The global gemcitabine HCl market has reached a size of US$ 727.5 million in 2023 and is forecasted to climb to US$ 1.43 billion by the end of 2033. Over the next ten years, Fact.MR’s research projects global demand for gemcitabine HCl to increase at 7% CAGR.

Gemcitabine hydrochloride is popularly known as chemotherapy called an antimetabolite, which kills cancer cells by preventing them from forming RNA and DNA. Gemcitabine HCl injection and drug is used for the treatment of various cancers such as pancreatic cancer, ovarian cancer, etc.

Surging number of cases of cancer around the world is projected to be the primary factor augmenting the consumption of gemcitabine HCl over the next ten years. Rising consumption of tobacco and alcohol, poor lifestyle choices, lack of physical activity, and poor eating habits are some of the leading factors that are resulting in the high incidence of cancer across the world.

• As per the World Health Organization (WHO) Cancer fact sheet, cancer was the leading cause of death in the world in 2020 and accounted for approximately 10 million deaths in that year.

Increasing demand for novel cancer treatments and growing awareness regarding cancer symptoms among the general population are also expected to supplement sales of gemcitabine HCl in the future. High investments in medical research and development around the world are also expected to create new business opportunities for gemcitabine HCl suppliers throughout the forecast period.

Low and middle-income countries are projected to be highly lucrative markets for gemcitabine HCl providers owing to rising spending on healthcare infrastructure development and growing demand for novel cancer treatments. The low availability of comprehensive treatment for cancer in these low and middle-income countries is also projected to favour gemcitabine HCl demand going forward.

• Less than 15% of low and middle-income countries have access to proper treatment for cancer, as per the statistics provided by the World Health Organization (WHO).

Patent expiry of old chemotherapy drugs, surging investments in oncology research, rising healthcare expenditure, and a rising number of new approvals for anticancer drugs by regulatory authorities are other influential prospects that could boost gemcitabine HCl drug sales through 2033.

Gemcitabine HCl is extensively used in the treatment of breast cancer and bladder cancer. The rising incidence of breast cancer around the world is also anticipated to create attractive business scope for established gemcitabine HCl companies as well as incoming gemcitabine HCl suppliers.

• As per statistics provided by the Breast Cancer Research Foundation (BCRF), around 2.3 million women were diagnosed with breast cancer in 2020 and it became the most common type of cancer in the world for the first time.

Report Attributes	Details
Gemcitabine HCl Market Size in 2023	US$ 727.5 Million
Projected Market Value (2033F)	US$ 1.43 Billion
Global Market Growth Rate (2023 to 2033)	7% CAGR
Market Share of North America (2022)	>35%
Asia Pacific Market Growth Rate (2023 to 2033)	7.2% CAGR
Key Companies Profiled	Eli Lilly and Company Sun Pharmaceutical Industries Ltd. Cornerstone Pharmaceuticals Inc. Accord-UK Ltd. Dr. Reddy’s Laboratories Ltd. Mylan N.V. Teva Pharmaceutical Industries Ltd. Ingenus Pharmaceuticals Hikma Pharmaceuticals plc Pfizer Inc. Fresenius Kabi AG

Which Region Has a Bullish Outlook for Gemcitabine HCl Demand?

“North America to Maintain Dominant Stance Over Decade”

Demand for gemcitabine HCl in the North American region accounts for a significant share at present and is projected to continue this dominance throughout the forecast period. The United States and Canada are estimated to be the most noteworthy markets in this region.

• In 2022, gemcitabine HCl shipments in North America accounted for more than 35% share of the global marketplace.

The presence of developed healthcare infrastructure, the growing availability of novel cancer treatment drugs, supportive government initiatives to promote medical R&D, the increasing caseload of cancer patients, and the growing number of approvals for new cancer drugs by the United States Food and Drug Administration (FDA) are key prospects that are projected to govern shipments of gemcitabine HCl in the United States over the next ten years.

• As per the statistics provided by the American Cancer Society, over 1.9 million new cases of cancer are expected to be recorded in the United States by the end of 2023.

Growing aging population, poor diet, high consumption of tobacco, increasing awareness regarding cancer treatment, and rising availability of novel cancer diagnostics and treatment procedures are prime factors that could potentially influence gemcitabine HCl sales in Canada through 2033.

• The Canadian Cancer Statistics 2022 Special Report published by the Canadian Cancer Society in November 2022, stated that nearly 233,990 people were estimated to be diagnosed with some type of cancer by the end of 2022.

In summary, all of the aforementioned aspects are expected to play a crucial role in maintaining high gemcitabine HCl demand in the North American region across the forecast period.

A detailed assessment of factors such as supply chain management, product standards, pricing trends, etc., and their effect on the regional and global level has been elaborately discussed in this latest gemcitabine HCl market research report by the skilled analysts at Fact.MR, a market research and competitive intelligence provider.

How Can Gemcitabine HCl Start-ups Penetrate the Marketplace?

“Increasing Investments in Cancer R&D – Prime Focus of New Companies”

Start-ups can focus on research and development of novel treatment approaches that utilize gemcitabine hydrochloride as the incidence of different types of cancers skyrockets around the world. New gemcitabine HCl companies can also focus on taking advantage of supportive government initiatives for oncology research to advance their business potential and compete with established gemcitabine HCl providers in the future.

Country-wise Insights

Which European Countries Should Gemcitabine HCl Companies Focus On?

“Germany, France, and Hungary to be Noteworthy Markets in Europe”

The incidence of different types of cancers is increasing rapidly in European countries such as Austria, France, Germany, Hungary, and the United Kingdom in recent years, which is slated to primarily augment gemcitabine HCl shipments in the European region going forward.

• As per an article published in The Cancer Atlas, nearly 3.9 million new cases of cancer were recorded in Europe in 2018.

High consumption of tobacco and alcohol is resulting in a high prevalence of cancers in France, which could create opportunities for gemcitabine hydrochloride vendors in the future. Increasing investments in healthcare infrastructure development, high investments in cancer research, a rising number of new approvals for cancer treatment products, and expanding senescent population are some common factors that are slated to influence gemcitabine HCl demand in almost all European countries over the coming years.

Why Should Gemcitabine HCl Suppliers Invest in Japan?

“High Cancer Mortality Rate – Prime Factor Boosting Gemcitabine Hydrochloride Demand”

Investments in Japan’s healthcare infrastructure development have been increasing in recent years owing to the growing burden of patients affected by chronic diseases and the rising geriatric population. Increasing incidence of different types of cancer and high mortality rate for the same are also projected to favor sales of gemcitabine HCl drugs in Japan over the coming years.

• As per research published on National Center for Biotechnology Information website, cancer has been the leading cause of death in Japan for more than 30 years.

Growing awareness regarding cancer therapeutics and the surging availability of novel cancer therapies and anticancer drugs in the country are also expected to uplift gemcitabine HCl sales across the forecast period.

Category-wise Insights

Why are Generic Gemcitabine HCl Drugs More Popular?

“Low Cost of Generic Drugs Driving Their Demand”

Based on type, the market for gemcitabine HCl is segmented into branded and generic.

Generic drugs account for a major share of the global gemcitabine HCl industry landscape at present and are estimated to maintain this authoritative share over the next ten years. Low costs and similar efficacy of generic drugs as compared to branded drugs make them a popular choice among patients and promote their preference.

Surging awareness regarding the efficacy of generic cancer drugs in the treatment of different types of cancers and the growing availability of generic drugs are other factors that could bolster growth in this segment going forward.

Competitive Landscape

Prime gemcitabine HCl companies are expected to benefit from the increasing number of clinical trials involving gemcitabine hydrochloride as investments in oncology research increase around the world.

• Cornerstone Pharmaceuticals Inc., a leading name in innovative cancer therapies, announced the completion of its Phase 1b clinical trial of CPI-613 (devimistat) in conjunction with cisplatin and gemcitabine for advanced unresectable biliary tract cancer treatment in August 2022.
• In November 2020, the United States Food and Drug Administration (FDA), approved the use of Pembrolizumab plus chemotherapy as treatment for patients with locally recurrent unresectable breast cancer whose tumors express PD-L1.

Collaborations, mergers, and acquisitions are also expected to be popular strategies among gemcitabine HCl providers to hasten the development and launch of novel gemcitabine HCl injectables. More information about new developments and strategies adopted by leading gemcitabine hydrochloride manufacturers to increase their market presence has been mentioned in this Fact.MR research analysis.

Key Segments of Gemcitabine HCl Industry Research

• By Type :

  • Branded
  • Generic

• By Application :

  • Pancreatic Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Non-Small-Cell Lung Carcinoma (NSCLC)
  • Others

• By End User :

  • Hospitals
  • Cancer Centers
  • Others

• By Region :

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA